Trial Profile
A Phase II Study of Anti-PD1 Monoclonal Antibody (Nivolumab, BMS-936558) Administered in Combination With Anti-LAG3 Monoclonal Antibody (Relatlimab, BMS-986016) in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics; Therapeutic Use
- 06 Sep 2023 Planned End Date changed from 31 Jul 2023 to 31 Jul 2027.
- 06 Sep 2023 Planned primary completion date changed from 31 Jul 2023 to 31 Jul 2027.
- 06 Sep 2023 Status changed from recruiting to active, no longer recruiting.